Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Tóm tắt
Ipilimumab is a novel immunomodulator demonstrating promising efficacy in treatment of melanoma and other cancers. The clinical benefit from ipilimumab can be hampered by the immure-related adverse events (irAEs) caused by dysregulation of host immune system. Ipilimumab associated hepatitis is also an important irAE, however, there have been limited descriptions of its clinicopathologic and imaging characteristics. We aim to describe the clinicopathologic and imaging characteristics of 6 patients who were diagnosed as ipilimumab associated hepatitis during the ipilimumab treatment for melanoma. The clinical features of these patients were as follows: (1) severe cases with systemic symptoms and highly increased level of liver function tests (LFTs), and (2) mild asymptomatic cases with mildly increased level of LFTs. In severe cases with ALT >1,000 IU/L, imaging findings were characterized by mild hepatomegaly, periportal edema, and periportal lymphadenopathy, while mild cases showed normal imaging findings. This spectrum of imaging findings in our series was similar to that of common causes of acute hepatitis. Among 3 cases with pathologic specimen, two cases showed severe panlobular hepatitis with prominent perivenular infiltrate with endothelialitis, suggestive of predominant injury to hepatocytes, while the other case showed mild portal mononuclear infiltrate around proliferated bile ductules, suggestive of predominant injury to bile ducts. In summary, ipilimumab associated hepatitis may demonstrate variable imaging findings according to its clinical severity, and histologically may manifest either as a predominant injury to hepatocytes (acute hepatitis pattern) or as a predominant injury to bile ducts (biliary pattern).
Tài liệu tham khảo
citation_journal_title=N Engl J Med; citation_title=Improved survival with ipilimumab in patients with metastatic melanoma; citation_author=FS Hodi, SJ O’Day, DF McDermott; citation_volume=363; citation_issue=8; citation_publication_date=2010; citation_pages=711-723; citation_doi=10.1056/NEJMoa1003466; citation_id=CR1
citation_journal_title=Semin Oncol; citation_title=Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy; citation_author=A Hoos, R Ibrahim, A Korman; citation_volume=37; citation_issue=5; citation_publication_date=2010; citation_pages=533-546; citation_doi=10.1053/j.seminoncol.2010.09.015; citation_id=CR2
citation_journal_title=AJR Am J Roentgenol; citation_title=Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy; citation_author=KN O’Regan, JP Jagannathan, N Ramaiya, FS Hodi; citation_volume=197; citation_issue=2; citation_publication_date=2011; citation_pages=W241-W246; citation_doi=10.2214/AJR.10.6032; citation_id=CR3
Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. doi:
10.1200/JCO.2012.41.6750
citation_journal_title=Semin Oncol; citation_title=The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications; citation_author=AM Giacomo, M Biagioli, M Maio; citation_volume=37; citation_issue=5; citation_publication_date=2010; citation_pages=499-507; citation_doi=10.1053/j.seminoncol.2010.09.007; citation_id=CR5
citation_journal_title=Clin Nucl Med; citation_title=Ipilimumab-induced colitis on FDG PET/CT; citation_author=A Lyall, HA Vargas, RD Carvajal, G Ulaner; citation_volume=37; citation_issue=6; citation_publication_date=2012; citation_pages=629-630; citation_doi=10.1097/RLU.0b013e318248549a; citation_id=CR6
citation_journal_title=AJR Am J Roentgenol; citation_title=Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy; citation_author=Y Bronstein, CS Ng, P Hwu, WJ Hwu; citation_volume=197; citation_issue=6; citation_publication_date=2011; citation_pages=W992-W1000; citation_doi=10.2214/AJR.10.6198; citation_id=CR7
citation_journal_title=Radiographics; citation_title=The infected liver: radiologic-pathologic correlation; citation_author=KJ Mortele, E Segatto, PR Ros; citation_volume=24; citation_issue=4; citation_publication_date=2004; citation_pages=937-955; citation_doi=10.1148/rg.244035719; citation_id=CR8
citation_journal_title=Dig Dis Sci; citation_title=Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma; citation_author=DE Kleiner, D Berman; citation_volume=57; citation_issue=8; citation_publication_date=2012; citation_pages=2233-2240; citation_doi=10.1007/s10620-012-2140-5; citation_id=CR9
citation_journal_title=Proc Natl Acad Sci U S A; citation_title=Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma; citation_author=GQ Phan, JC Yang, RM Sherry; citation_volume=100; citation_issue=14; citation_publication_date=2003; citation_pages=8372-8377; citation_doi=10.1073/pnas.1533209100; citation_id=CR10
citation_journal_title=Ann Oncol; citation_title=Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study; citation_author=SJ O’Day, M Maio, V Chiarion-Sileni; citation_volume=21; citation_issue=8; citation_publication_date=2010; citation_pages=1712-1717; citation_doi=10.1093/annonc/mdq013; citation_id=CR11
citation_journal_title=J Clin Oncol; citation_title=Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy; citation_author=KD Chmiel, D Suan, C Liddle; citation_volume=29; citation_issue=9; citation_publication_date=2011; citation_pages=e237-e240; citation_doi=10.1200/JCO.2010.32.2206; citation_id=CR12
citation_journal_title=Immunol Rev; citation_title=Twelve immunotherapy drugs that could cure cancers; citation_author=MA Cheever; citation_volume=222; citation_publication_date=2008; citation_pages=357-368; citation_doi=10.1111/j.1600-065X.2008.00604.x; citation_id=CR13